Phillips C F
Hosp Pract. 1979 Feb;14(2):75-80. doi: 10.1080/21548331.1979.11707484.
The possible benefits and dangers of a vaccine program for CMV infection, especially congenital infection, cannot be rationally analyzed until more is known about the virus itself, including its manner of spread and the nature of host responses. Until then, trials with the experimental vaccines under development should be limited to patients at unusually high risk, such as those receiving renal transplants.
在对巨细胞病毒（CMV）本身有更多了解之前，包括其传播方式和宿主反应的性质，就无法对针对CMV感染，尤其是先天性感染的疫苗计划的潜在益处和风险进行合理分析。在此之前，正在研发的实验性疫苗的试验应仅限于高危患者，如接受肾移植的患者。
